Quick Answer
KYNTRA BIO, INC. reported Revenue (ASC 606) of $6.44 million for fiscal year 2025.
KYNTRA BIO, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $6.44M | -78.3% |
| 2024 | $29.62M | -36.7% |
| 2023 | $46.80M | -66.7% |
| 2022 | $140.73M | -40.2% |
| 2021 | $235.31M | +33.5% |
| 2020 | $176.32M | -31.3% |
| 2019 | $256.58M | +20.5% |
| 2018 | $212.96M | +62.6% |
| 2017 | $131.00M | -28.5% |
| 2016 | $183.19M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.08M | +774.8% | -20.2% |
| June 30, 2025 | $1.35M | +35.1% | -50.8% |
| March 31, 2025 | $2.74M | -89.2% | +2126.8% |
| September 30, 2024 | $123.0K | -99.7% | -87.7% |
| June 30, 2024 | $998.0K | -97.7% | -96.1% |
| March 31, 2024 | $25.36M | -29.9% | -36.8% |
| September 30, 2023 | $40.13M | +155.1% | -9.4% |
| June 30, 2023 | $44.32M | +48.7% | +22.6% |
- KYNTRA BIO, INC. showed a decrease of -78.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, KYNTRA BIO, INC.’s revenue (asc 606) has declined by 96.5% (from $183.19 million to $6.44 million).
- The most recent figure is from KYNTRA BIO, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: